Forest Laboratories and Adamas Pharmaceuticals have signed a licensing deal for the development and commercialisation of a fixed dosed combination (FDC) of Namenda XR and donepezil HCl to treat Alzheimer’s disease in the US.

According to the agreement, the companies will partner to develop the FDC but Forest will hold exclusive US commercialisation rights, and is responsible for all development and commercialisation activities.

The FDC product, which will be patent protected until 2029, is expected to launch in 2015 following FDA approval.

Forest chairman, CEO and president Howard Solomon said studies have shown that Namenda and donepezil used together improve cognition, function and behaviour in some patients with moderate-to-severe Alzheimer’s disease.

"This new fixed combination, which reduces the pill requirement from three tablets to one and the dosing frequency from two times per day to once per day, can benefit physicians, caregivers, and patients," Solomon said.

Under the agreement, Forest will make a $65m upfront payment to Adamas which is even eligible to receive $95m in future development and FDA approval milestones along with royalties on net sales in the US.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Adamas CEO Gregory Went said; "This collaboration will accelerate this innovative product’s development towards a 2014 US NDA filing, and allow Adamas to focus our attention on the ex-US market for the product and to continue the ongoing development of Nurelin, our late-stage product candidate for the treatment of CNS disorders, including Parkinson’s disease."